SymBio Pharmaceuticals Limited

4582

JP3383050006

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
175 ^JPY	-1.69%		-2.23%	-29.15%

Apr. 19	SymBio Pharmaceuticals Limited announced that it has received ¥196.35 million in funding from Evolution Capital Management LLC	CI
Mar. 18	SymBio Pharmaceuticals Limited amended terms of the transaction	CI

SymBio Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended March 31, 2021

May 13, 2021 at 02:30 am EDT

SymBio Pharmaceuticals Limited announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was JPY 1,420.332 million compared to JPY 551.369 million a year ago. Operating loss was JPY 210.518 million compared to JPY 961.910 million a year ago. Net loss was JPY 209.659 million compared to JPY 992.170 million a year ago.

Latest news about SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited announced that it has received ¥196.35 million in funding from Evolution Capital Management LLC	Apr. 18	CI
SymBio Pharmaceuticals Limited amended terms of the transaction	Mar. 17	CI
SymBio Pharmaceutical's FY2023 Earnings Miss Forecast Due to Higher Than Expected Operating Loss	Feb. 12	MT
SymBio Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2024	Feb. 08	CI
SymBio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2023	Feb. 08	CI
SymBio Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
SymBio Pharmaceuticals Adjusts Forecasts to Reflect Shrinking Market Demand	Nov. 15	MT
Symbio Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2023	Nov. 14	CI
SymBio Pharmaceuticals Limited Reports Earnings Results for the Nine Months Ended September 30, 2023	Nov. 14	CI
SymBio Pharmaceuticals Limited amended terms of the transaction	Nov. 09	CI
SymBio Pharmaceuticals Limited announced that it expects to receive ¥2.208 billion in funding from Evolution Capital Management LLC	23-10-05	CI
SSymBio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2023	23-08-03	CI
SymBio Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-03	CI
SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	23-04-27	CI
SymBio Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Symbio Pharmaceuticals Signs Cooperative R&D Deal to Investigate Brincidofovir's Efficacy in EBV Diseases	23-04-25	MT
SymBio Pharmaceuticals Limited Enters into A Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases	23-04-23	CI
SymBio Pharmaceuticals Limited Enters into Collaborative Research and Development Agreement with National Institute of Neurological Disorders and Stroke	23-03-22	CI
SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023	23-02-09	CI
SymBio Pharmaceuticals Limited Reports Earnings Results for the Nine Months Ended September 30, 2022	22-11-08	CI
Symbio Pharmaceuticals Limited Revises Earnings Forecast for the Period from January 1, 2022 to December 31, 2022	22-11-08	CI
SymBio Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-04	CI
Symbio Pharmaceuticals Limited Revises Earning Guidance for Fiscal Year Ending December 31, 2022	22-08-04	CI
SymBio Pharmaceuticals Limited announced that it has received ¥675.76 million in funding from CVI Investments, Inc.	22-05-31	CI
SymBio Pharmaceuticals Limited announced that it expects to receive ¥675.76 million in funding from CVI Investments, Inc.	22-05-15	CI

Chart SymBio Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

SymBio Pharmaceuticals Limited is a Japan-based pharmaceutical company. Along with medicine specialists, contract research organizations (CROs) and other pharmaceutical companies, the Company is engaged in the design and operation of clinical tests, the manufacture and sale of new drugs specializing in three therapeutic areas: cancer, blood diseases and autoimmune diseases. The Company develops new medicines using chemical compounds proofed by preclinical tests and clinical tests. The Company manufactures and sells medicines through domestic and foreign pharmaceutical companies. The Company's pipelines include anticancer drugs, such as SyB L-0501, SyB L-1101 and SyB C-1101.

Sector

Pharmaceuticals

Calendar

2024-05-06 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SYMBIO PHARMACEUTICALS LIMITED	-29.15%	52.42M
ELI LILLY AND COMPANY	+26.21%	653B
NOVO NORDISK A/S	+27.00%	556B
JOHNSON & JOHNSON	-6.61%	354B
MERCK & CO., INC.	+20.34%	331B
ABBVIE INC.	+2.65%	296B
ASTRAZENECA PLC	+13.09%	233B
NOVARTIS AG	+5.46%	201B
ROCHE HOLDING AG	-9.61%	193B
AMGEN INC.	-6.24%	144B

Other Pharmaceuticals